Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA FINANCIAL DISCLOSURE REG WOULD APPLY TO DATA SUBMITTED UNDER OTC MONOGRAPHS

This article was originally published in The Tan Sheet

Executive Summary

FDA FINANCIAL DISCLOSURE REG WOULD APPLY TO DATA SUBMITTED UNDER OTC MONOGRAPHS, the agency stated in a proposed role on "Financial Disclosure by Clinical Investigators," published in the Sept. 22 Federal Register. The disclosure requirements would apply to "clinical data submitted as part of the over-the-counter monograph process," FDA explained, adding that it believes data "submitted for OTC products are no less important than data submitted as part of the NDA or ANDA processes and should be treated similarly." FDA added that it will extend the proposal to foods and animal drugs in a future notice.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS083252

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel